Vanda Pharmaceuticals | VNDA - Ordinary Share Capital


Vanda Pharmaceuticals reported $58K in Ordinary Share Capital for its fiscal quarter ending in December of 2024.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 4.93M Mar/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Moderna USD 391M 2M Sep/2025
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Sanofi EUR 1.21B 8.25M Mar/2026
Takeda JPY 1.58B 460K Jun/2026
Teva Pharmaceutical Industries USD 1.16B 1000K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Veracyte USD 79.79M 1000 Jun/2026